Recombinant CFH-Binding Proteins for Complement Amplification Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods and compositions that can selectively bind complement components, particularly human complement factor H (CFH), to solid supports and modulate complement activity, as an improperly regulated complement system can cause damage to host or self-cells and exacerbate various diseases.
Innovation Solution
A recombinant protein derived from bacterial proteins, such as Streptococcus pneumoniae PspC, is developed to bind to CFH, enhancing its affinity for C3d and C3b, thereby inhibiting C3b amplification in the alternative complement pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CFH is used to protect self-surfaces from complement-mediated damage, then host cell protection is improved, but pathogens can exploit CFH for their own purposes
Solution Approach 1:
The invention uses truncated versions of PspC protein that contain only specific functional domains (such as the N-terminal domain or specific CCP modules) required for CFH binding. This segmentation allows the therapeutic agent to capture CFH effectively while removing domains that facilitate pathogen exploitation, thus resolving the contradiction between protection and vulnerability.
Solution Approach 2:
The invention extracts and utilizes only the essential CFH-binding functionality from the PspC protein structure. By taking out the specific domains responsible for CFH interaction and creating isolated functional fragments, the therapy achieves selective CFH capture without the harmful pathogen-associated functions, thereby protecting host cells while preventing pathogen exploitation.
2Reliability
If PspC is used to bind and modulate CFH activity, then complement regulatory activity is improved, but the complexity of producing and characterizing the protein increases
Solution Approach 1:
The invention divides the full-length PspC protein into smaller, functionally distinct truncated versions containing specific domains. This segmentation simplifies production by reducing the size and complexity of the protein to be expressed and purified, while also facilitating characterization by focusing on specific functional regions. The truncated proteins maintain essential CFH-binding activity while being more tractable for manufacturing and analysis.
3Reliability
If CFH binds to C3b and C3d with high affinity, then complement amplification is controlled, but the ability to selectively bind CFH for therapeutic purposes becomes challenging
Solution Approach 1:
The invention introduces truncated PspC protein as an intermediary agent that mediates selective CFH capture. This intermediary has high affinity for CFH but does not directly compete with CFH's natural binding to C3b and C3d. Instead, it acts as a bridging molecule that sequesters CFH in a controlled manner, allowing the therapy to modulate complement activity while preserving the essential CFH-C3b/C3d interactions needed for proper regulatory function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant protein effectively stabilizes a conformation of CFH that enhances its regulatory activity, providing therapeutic potential for conditions associated with aberrant complement activity, such as atypical haemolytic uraemic syndrome, dense deposit disease, and age-related macular degeneration.
Implementation Method 1
a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH
Implementation Method 2
In experiments conducted using surface plasmon resonance, the PspCN:CFH complex was found to bind at least threefold better than CFH to immobilised C3b
Implementation Method 3
The recombinant protein effectively stabilizes a conformation of CFH that enhances its regulatory activity
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3D
AI summary
The present invention provides a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH.